SCHEMBL4486848

SCHEMBL4486848

CC(=O)Nc1ccc(C(Nc2ccc(N(C)C(=O)CN3CCN(C)CC3)cc2)=C2C(=O)Nc3cc(Cl)ccc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.42
LRRK2 Q5S007 1/20 0.40
GHSR Q92847 3/20 0.38
ABL1 P00519 1/20 0.38
NTRK1 P04629 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
FGFR1 P11362 1/20 0.38
PDGFRA P16234 1/20 0.38
FLT1 P17948 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
NTRK3 Q16288 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486843 1.00 AAK1 (0.42) AAK1LRRK2GHSRABL1NTRK1
SCHEMBL226539 0.96 AAK1 (0.44) AAK1GHSRABL1NTRK1CSF1R
SCHEMBL226540 0.96 AAK1 (0.44) AAK1GHSRABL1NTRK1CSF1R
SCHEMBL4500944 0.94 AAK1 (0.42) AAK1GHSRABL1NTRK1CSF1R
SCHEMBL4500938 0.94 AAK1 (0.42) AAK1GHSRABL1NTRK1CSF1R
SCHEMBL4497442 0.93 AAK1 (0.42) AAK1GHSRABL1NTRK1CSF1R
SCHEMBL4497450 0.93 AAK1 (0.42) AAK1GHSRABL1NTRK1CSF1R
SCHEMBL4485414 0.93 AAK1 (0.46) AAK1GHSRABL1NTRK1CSF1R
SCHEMBL4485411 0.93 AAK1 (0.46) AAK1GHSRABL1NTRK1CSF1R
SCHEMBL226833 0.93 AAK1 (0.40) AAK1GHSRABL1NTRK1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US claimed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US claimed
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR AAK1 1080/4885LRRK2 168/4885GHSR 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.